| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Vishal Sehgal | |
| JohnA Consalvo | |||
| Rinku Sehgal | |||
| SukhminderJit Singh Bajwa | |||
| P2860 | cites work | Aging, diabetes, and the public health system in the United States | Q26852929 |
| Stress-induced hyperglycemia | Q32060199 | ||
| The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease | Q34237283 | ||
| Genital mycotic infections in patients with diabetes | Q34349532 | ||
| The health burden of diabetes for the elderly in four communities | Q34454281 | ||
| Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Q34646948 | ||
| Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. | Q34647844 | ||
| Endocrine emergencies in critically ill patients: Challenges in diagnosis and management | Q36331611 | ||
| Clinical and critical care concerns in severely ill obese patient | Q36331619 | ||
| Peri-operative renal protection: The strategies revisited | Q36426215 | ||
| Management of diabetes mellitus in older persons | Q36459718 | ||
| Diabeto-anaesthesia: A subspecialty needing endocrine introspection | Q36536866 | ||
| Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Q36845771 | ||
| Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study | Q37022726 | ||
| Cognitive impairment: an increasingly important complication of type 2 diabetes: the age, gene/environment susceptibility--Reykjavik study | Q37306134 | ||
| Candidiasis: An unusual cause of persistent high-grade fever in mid-pregnancy | Q37443204 | ||
| Polypharmacy and potentially inappropriate medication use as the precipitating factor in readmissions to the hospital | Q37487515 | ||
| Canagliflozin for the treatment of type 2 diabetes | Q38117601 | ||
| Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia | Q38873457 | ||
| An acute need for awareness of insulin injection guidelines in operative and intensive care units | Q41055469 | ||
| Logical empiricism in anesthesia: A step forward in modern day clinical practice | Q41833231 | ||
| Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial | Q43804231 | ||
| Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial | Q44452805 | ||
| Clinical characterisation of severe hypoglycaemia--a prospective population-based study | Q44603629 | ||
| Vulvovaginal candidiasis in children and adolescents with type 1 diabetes mellitus | Q45167478 | ||
| Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. | Q51337136 | ||
| Hemoglobin A1c for the diagnosis of diabetes: practical considerations | Q82875218 | ||
| Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects | Q83764954 | ||
| Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study | Q84047593 | ||
| Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications | Q85013789 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 227-31 | |
| P577 | publication date | 2014-10-01 | |
| P1433 | published in | Journal of Pharmacology & Pharmacotherapeutics | Q15816637 |
| P1476 | title | Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon | |
| P478 | volume | 5 |
| Q57816534 | 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus |
| Q86812936 | Erratum: Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon: Erratum |
| Q36316732 | Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use. |
| Q38737061 | Special considerations for the treatment of chronic kidney disease in the elderly. |
| Q38836416 | Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit |
Search more.